Press Release: CBSET and CILcare partner to offer cutting-edge preclinical research services for the evaluation of hearing disorders and regenerative therapies

– “This partnership brings together CBSETs preclinical surgery, drug delivery, and histopathology expertise with CILcare’s proprietary functional tests for assessing alterations to the auditory system in GLP-compliant state-of-the-art facilities. Our new services will enable companies to accelerate their development of novel therapies for hearing loss and be instrumental in supporting their regulatory submissions.” – Peter […]

Press Release: CBSET expands its preclinical research services by adding GLP-compliant cell-based-therapies support capability

Company to launch new service at next week’s “ISSCR 2017 Annual Meeting” “CBSET is the ideal partner in preparing, presenting, and defending GLP studies for regulatory review.”—Michael Naimark, CBSET LEXINGTON, Mass., June 8, 2017  — CBSET Inc., a non-profit GLP translational research institute that specializes in the advancement of novel therapies, announced today that it has […]

Press Release: Safety and Efficacy of New Class of Orthopedic Implant for Intramedullary Biologic Stabilization of Fractured Long Bones Studied Out to 1 Year

CBSET, IlluminOss Medical Data Published in Journal of Orthopaedic Research IlluminOss* System provides minimally invasive approach designed to replace splints, casts, metal fixator plates and rods to stabilize broken bones LEXINGTON, Mass., March 23, 2017 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today it […]

Press Release: CBSET appoints Rami Tzafriri PhD as Director of Research and Innovation

LEXINGTON, Mass., Oct 28, 2016 — CBSET Inc. announced today that it has appointed Dr. Rami Tzafriri as Director of Research and Innovation. Since 2009, Dr. Tzafriri has held the position of Principal Scientist at CBSET, where he developed quantitative computational and experimental methods for evaluating combination drug and energy delivery devices. He is best known […]

Press Release: CBSET appoints Michael Naimark as Director of Business Development

LEXINGTON, Mass., Oct 27, 2016 — CBSET, Inc. announced today that it has appointed Michael Naimark as Director of Business Development, effective immediately. Most recently, he was employed by the Neural Stem Cell Institute (NSCI) as project manager overseeing the development of a cell-based therapy for macular degeneration under a 4-year award from the New York Stem […]

News Advisory: You Need To Know: Endovascular Drug Delivery Is Experiencing a Resurgence in Innovation

“Understanding and computationally modeling the determinants of drug release kinetics and tissue distribution can help further drive innovation at reduced cost.” – Rami Tzafriri, PhD, Principal Scientist, CBSET “Endovascular Drug Delivery and Drug Elution Systems: First Principles” Abraham Rami Tzafriri, PhD Elazer Reuven Edelman, MD, PhD “…The first principles outlined…serve as a handbook for features […]

Press Release: A Paradigm for Safety Assessment of Energy-Based Devices: CBSET Presents In Vivo Data at SoT 2016

“We have developed a preclinical paradigm for predictably modulating the efficacy of thermal ablation devices while minimizing adverse effects on target and surrounding tissues,” said Dr. John H. Keating, Director of Pathology, CBSET. LEXINGTON, Mass., March 10, 2016 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical […]

Press Release: MANTA Vascular Closure Device Safely and Effectively Closes Large Bore Arterial Access Sites: CBSET to Present Preclinical Data at ICI 2015

“Vascular access complications are a significant source of morbidity, especially for interventions such as TAVR that require large bore cannulation,” said Haim Danenberg, M.D., CBSET’s chief scientific advisor. “CBSET’s study demonstrates that MANTA is a safe and reliable large-bore percutaneous closure device.” LEXINGTON, Mass., Dec. 10, 2015 — Scientists at CBSET, a not-for-profit preclinical research […]

Press Release: Data provides new insights into the optimal balance between drug-eluting stent coating material properties and drug elution kinetics

“Drug eluting stents remain a ripe field for continued innovation. Until now, the focus on sustainable drug elution has strictly limited the choice of DES coating materials. Our study results confirm a new paradigm for optimizing coating biocompatibility,” said Rami Tzafriri, PhD, Principal Scientist, CBSET. LEXINGTON, Mass., Oct. 28, 2015 — CBSET, a not-for-profit preclinical […]

Press Release: Primary lesion treatment using Diamondback 360® orbital atherectomy system enhances paclitaxel deposition in calcified peripheral arteries: preclinical data presented at EuroPCR 2015

““This preclinical study could have a significant clinical impact by demonstrating improved drug delivery after modification of calcified lesions,” said Gunnar Tepe, M.D., RoMed Hospital, Rosenheim, Germany. LEXINGTON, Mass., May 20, 2015 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed today that modification of atherosclerotic […]